Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in Interest ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

SAB Biotherapeutics (SABS) Cash from Operations (2020 - 2025)

SAB Biotherapeutics (SABS) has disclosed Cash from Operations for 6 consecutive years, with 16776327.0 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Cash from Operations fell 76.0% year-over-year to 16776327.0, compared with a TTM value of 44775111.0 through Dec 2025, down 30.57%, and an annual FY2025 reading of 44775111.0, down 30.57% over the prior year.
  • Cash from Operations was 16776327.0 for Q4 2025 at SAB Biotherapeutics, down from 13050023.0 in the prior quarter.
  • Across five years, Cash from Operations topped out at 9453495.0 in Q1 2021 and bottomed at 16776327.0 in Q4 2025.
  • Average Cash from Operations over 5 years is 6282958.15, with a median of 6768720.0 recorded in 2021.
  • The sharpest move saw Cash from Operations tumbled 48526.09% in 2021, then skyrocketed 83.16% in 2023.
  • Year by year, Cash from Operations stood at 4878169.0 in 2021, then surged by 68.12% to 1555024.0 in 2022, then tumbled by 764.73% to 13446717.0 in 2023, then grew by 29.11% to 9532188.0 in 2024, then plummeted by 76.0% to 16776327.0 in 2025.
  • Business Quant data shows Cash from Operations for SABS at 16776327.0 in Q4 2025, 13050023.0 in Q3 2025, and 7151544.0 in Q2 2025.